secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0000914475-25-000157
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine Biosciences Q2 2025: Revenue $687.5M up 16.5% YoY; valbenazine Phase 3 schizophrenia miss
--------------------------------------------------------------------------------

- Total revenue $687.5M; INGREZZA $624.4M (+8% YoY), CRENESSITY $53.2M (launch year).
- GAAP diluted EPS $1.06 (vs $0.63 Q2 2024); Non-GAAP diluted EPS $1.65 (vs $1.63).
- INGREZZA 2025 net product sales guidance narrowed to $2.50-2.55B from $2.50-2.60B.
- CRENESSITY: 664 new patient enrollment start forms in Q2; 76% reimbursement coverage for dispensed scripts.
- Phase 3 study of valbenazine for adjunctive schizophrenia did not meet primary endpoint; safety consistent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447525000157/0000914475-25-000157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447525000157/nbix-20250730.htm
  HTML page:      https://secwatch.observer/filing/0000914475-25-000157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer